Biondvax Pharmaceuticals Ltd

BiondVax Announces Positive Phase IIa Results for Universal Flu Vaccine

BiondVax Begins Phase IIa Study for Universal Flu Vaccine

Frost & Sullivan Awards "2010 European Influenza Vaccines Technology Innovation Award" to BiondVax Pharmaceuticals for Universal Influenza Vaccine

BiondVax's Multimeric-001 Universal Flu Vaccine was Found to be Safe and to Activate Both Arms of the Human Immune System, Inducing an Elevated Level of Antibodies in all Participants

NESS ZIONDA, Israel, June 16, 2011 - BiondVax's Multimeric-001 Universal Influenza Vaccine Successfully Meets Primary and Secondary Endpoints With Strong Safety and Immunogenicity Data in 200 Participants BiondVax Pharmaceuticals Ltd.

MORE..

NESS ZIONA, Israel, October 11, 2010 - BiondVax Pharmaceuticals Ltd.

MORE..

NESS ZIONA, Israel, July 28, 2010 - Frost & Sullivan is pleased to announce the award of its prestigious 2010 European Influenza Vaccines Technology Innovation Award (www.biondvax.com/image/users/128084/ftp/my_files/Documents/BiondVax%20-%20Technology%20Innovation.pdf?id=3635857)to BiondVax Pharmaceuticals ("BiondVax") (www.biondvax.com/) for their breakthrough work on a universal influenza vaccine.

MORE..

Older News

RECHOVOT, Israel, December 7 - - 60 people, males and females, aged 18-49, participated in the trial - The antibodies generated by the vaccine specifically identified several strains of influenza, including the swine flu strain - BiondVax's CEO Dr.

MORE..